LeMaitre resumed with a Buy at Roth Capital. Roth Capital analyst Scott Henry resumed coverage of LeMaitre Vascular with a Buy rating and $38 price target, as he expects resumed sales-force expansion to drive organic growth in the near-term and thinks the company’s Reddick divestiture could help fund an acquisition, which could be a catalyst.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.